JP2024514843A5 - - Google Patents

Info

Publication number
JP2024514843A5
JP2024514843A5 JP2023561779A JP2023561779A JP2024514843A5 JP 2024514843 A5 JP2024514843 A5 JP 2024514843A5 JP 2023561779 A JP2023561779 A JP 2023561779A JP 2023561779 A JP2023561779 A JP 2023561779A JP 2024514843 A5 JP2024514843 A5 JP 2024514843A5
Authority
JP
Japan
Prior art keywords
once
days
seizures
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514843A (ja
Filing date
Publication date
Priority claimed from US17/225,654 external-priority patent/US12016829B2/en
Application filed filed Critical
Priority claimed from PCT/IB2022/053271 external-priority patent/WO2022215030A1/en
Publication of JP2024514843A publication Critical patent/JP2024514843A/ja
Publication of JP2024514843A5 publication Critical patent/JP2024514843A5/ja
Pending legal-status Critical Current

Links

JP2023561779A 2021-04-08 2022-04-07 発作性疾患を治療するための医薬組成物及び方法 Pending JP2024514843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/225,654 2021-04-08
US17/225,654 US12016829B2 (en) 2019-10-11 2021-04-08 Pharmaceutical composition and method for treating seizure disorders
PCT/IB2022/053271 WO2022215030A1 (en) 2021-04-08 2022-04-07 Pharmaceutical composition and method for treating seizure disorders

Publications (2)

Publication Number Publication Date
JP2024514843A JP2024514843A (ja) 2024-04-03
JP2024514843A5 true JP2024514843A5 (https=) 2025-04-14

Family

ID=83546168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561779A Pending JP2024514843A (ja) 2021-04-08 2022-04-07 発作性疾患を治療するための医薬組成物及び方法

Country Status (7)

Country Link
EP (1) EP4319730A4 (https=)
JP (1) JP2024514843A (https=)
CN (1) CN117479930A (https=)
AU (1) AU2022255944A1 (https=)
CA (1) CA3213953A1 (https=)
MX (1) MX2023011821A (https=)
WO (1) WO2022215030A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
US20190083388A1 (en) * 2017-09-19 2019-03-21 Zynerba Pharmaceuticals, Inc. Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions
BR112022004175A2 (pt) * 2019-09-17 2022-05-31 Zynerba Pharmaceuticals Inc Tratamento de encefalopatia de syngap1
EP4041209A4 (en) * 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
KR20230113622A (ko) * 2020-12-03 2023-07-31 지네르바 파마슈티컬스, 인코포레이티드 난치성 발작의 치료를 위한 칸나비디올

Similar Documents

Publication Publication Date Title
JP2023523155A5 (https=)
AU2020361741B2 (en) Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
JP2022551696A5 (https=)
US20250108043A1 (en) Continuous delivery of lenalidomide and other immunomodulatory agents
JP2024514843A5 (https=)
RU2004131866A (ru) Форма для трансэпикутального введения для лечения синдрома усталых ног
US8852628B1 (en) Transdermal drug delivery system for diclofenac
JP2022550569A5 (https=)
JP2016505006A (ja) レボノルゲストレル及びエチニルエストラジオール用の経皮薬物送達システム
JP2023520845A (ja) ヒドロキシクロロキン及び／又はクロロキンを含む経口送達システム
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
WO2021211558A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
JP2024513961A5 (https=)
HK40084062A (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders